|
|
|
| home > ict > winter 2020 > we can do better: key considerations for paediatric trial success |
|
|
 PUBLICATIONS |
International Clinical Trials
|
Parents naturally become anxious when their children are unwell, and that is generally increased when the child needs hospital treatment or when certain procedures, surgery, or conditions are mentioned. In such settings, parents may not be immediately receptive to enquiries about their child participating in clinical research. However, once the discussion with the investigator is underway, a range of additional obstacles often come to the surface, many of which we have the ability to minimise.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
About the author
Mark Sorrentino, MD and MS, Vice President of the Center for Pediatric Clinical Development, at PRA Health Sciences has more than 20 years of experience in the pharma and biotechnology industries and currently leads PRA’s global paediatric centre of excellence. Mark holds an appointment as an Assistant Clinical Professor at the George Washington University School of Medicine, US. Prior to joining PRA, he spent five years as the Global Chair and Founder of the paediatric practice area at a leading CRO, overseeing all aspects of strategy and paediatric clinical development, and the Global Therapeutic Head of Critical Care.
|
|
|
|
|
|
 |
News and Press Releases |
 |
Rare and orphan disease expert Terebellum launches market access guide
Terebellum, subsidiary of global specialty pharmacy and healthcare
solutions organisation AscellaHealth, is launching a strategic guide to
help manufacturers bring rare disease products to market.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models
DrugDev
For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality.
One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >> |
|
|
